Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity

Reddy, D. Narasimha; Kongot, Manasa; Kumar, Amit

doi:10.1016/j.tube.2020.102050

Cited by 55 publications

(32 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, developing potent TB drugs is one of our primary aims, [3,9,[140][141][142] and we are confident that this review article will contribute to the development of more potent anti-TB agents with significantly improved results.…”

Section: Discussionmentioning

confidence: 99%

Drug re‐engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery

Reddy

Sinha

Kumar

et al. 2022

Archiv der Pharmazie

View full text Add to dashboard Cite

The prevalence of tuberculosis (TB) remains the leading cause of death from a single infectious agent, ranking it above all other contagious diseases. The problem to tackle this disease seems to become even worse due to the outbreak of SARS-CoV-2.Further, the complications related to drug-resistant TB, prolonged treatment regimens, and synergy between TB and HIV are significant drawbacks. There are several drugs to treat TB, but there is still no rapid and accurate treatment available.Intensive research is, therefore, necessary to discover newer molecular analogs that can probably eliminate this disease within a short span. An increase in efficacy can be achieved through re-engineering old TB-drug families and repurposing known drugs.These two approaches have led to the production of newer classes of compounds with novel mechanisms to treat multidrug-resistant strains. With respect to this context, we discuss structural aspects of developing new anti-TB drugs as well as examine advances in TB drug discovery. It was found that the fluoroquinolone, oxazolidinone, and nitroimidazole classes of compounds have greater potential to be further explored for TB drug development. Most of the TB drug candidates in the clinical phase are modified versions of these classes of compounds. Therefore, here we anticipate that modification or repurposing of these classes of compounds has a higher probability to reach the clinical phase of drug development. The information provided will pave the way for researchers to design and identify newer molecular analogs for TB drug development and also broaden the scope of exploring future-generation potent, yet safer anti-TB drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug re‐engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery

Reddy

Sinha

Kumar

et al. 2022

Archiv der Pharmazie

View full text Add to dashboard Cite

show abstract

“…13 First time coumarin is isolated from tonka beans by Vogel in 1820 and is first synthesized by Perkin in 1868. 14 Coumarin-based compounds have attracted much attention by organic/medicinal chemists and drug design scientists as a consequence of their diverse pharmacological and biological properties such as antimicrobial, [15][16][17] anticancer, [18][19][20] anti-inflammatory, 21 antidepressant, 22 antioxidant, 23 antituberculosis, 24,25 anti-Alzheimer, 26,27 antinociceptive, 28 anti-edematogenic, 28 antileishmanial, 29 antiviral, 30,31 analgesic, 32 anti-pyretic, 32,33 antimalarial, 34,35 antithrombotic, 36 antitumor, [37][38][39] antiretroviral, 40 anti-coagulation, 41 antiasthmatic, 42 anti-influenza 43 and antihyperlipidemic. 44 Moreover, some of the coumarin derivatives have been demonstrated to be potent selective human carbonic anhydrase (CA), 45 Mcl-1, 46 SARS-CoV-2, 47 MAO-B, 48 inhibition of xanthine oxidase, 49 inhibition of lipoxygenase, 50 topoisomerase IV 51 and, also DNA gyrase inhibitor.…”

Section: What Is K Nown and Objec Tivementioning

confidence: 99%

Synthetic and natural coumarins as potent anticonvulsant agents: A review with structure–activity relationship

Keri

Budagumpi

Somappa

2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What is known and objective:The main objective of this review is to highlight the most relevant studies since 1990 (to date) in the area of medicinal chemistry aspects to provide a panoramic view to the biologists/medicinal chemists working in this area and would assist them in their efforts to design, synthesize and extract (from natural source) coumarin-based anticonvulsant agents. Also, the structure-activity relationship (SAR) studies are also discussed for further rational design of this kind of derivatives. It is hoped that this review will be helpful for new thoughts in the quest for rational designs of more active and less toxic coumarin-based antiepileptic agents.

show abstract

“…These are benzopyrone compounds belonging to the flavonoid-like moiety of secondary metabolites. Opposite to a widely distributed opinion attributing coumarins to a group of mainly plant secondary metabolites, a large portion of the presently known coumarins exceeding 1300 [ 3 , 4 ] have been identified in bacteria and fungi [ 5 , 6 ]. Moreover, fungi occurred to be the most effective source of the coumarin-based products of pharmaceutical importance, never-before seen.…”

Section: Introductionmentioning

confidence: 99%

Coumarins as Fungal Metabolites with Potential Medicinal Properties

2022

View full text Add to dashboard Cite

Coumarins are a structurally varied set of 2H-chromen-2-one compounds categorized also as members of the benzopyrone group of secondary metabolites. Coumarin derivatives attract interest owing to their wide practical application and the unique reactivity of fused benzene and pyrone ring systems in molecular structure. Coumarins have their own specific fingerprints as antiviral, antimicrobial, antioxidant, anti-inflammatory, antiadipogenic, cytotoxic, apoptosis, antitumor, antitubercular, and cytotoxicity agents. Natural products have played an essential role in filling the pharmaceutical pipeline for thousands of years. Biological effects of natural coumarins have laid the basis of low-toxic and highly effective drugs. Presently, more than 1300 coumarins have been identified in plants, bacteria, and fungi. Fungi as cultivated microbes have provided many of the nature-inspired syntheses of chemically diverse drugs. Endophytic fungi bioactivities attract interest, with applications in fields as diverse as cancer and neuronal injury or degeneration, microbial and parasitic infections, and others. Fungal mycelia produce several classes of bioactive molecules, including a wide group of coumarins. Of promise are further studies of conditions and products of the natural and synthetic coumarins’ biotransformation by the fungal cultures, aimed at solving the urgent problem of searching for materials for biomedical engineering. The present review evaluates the fungal coumarins, their structure-related peculiarities, and their future therapeutic potential. Special emphasis has been placed on the coumarins successfully bioprospected from fungi, whereas an industry demand for the same coumarins earlier found in plants has faced hurdles. Considerable attention has also been paid to some aspects of the molecular mechanisms underlying the coumarins’ biological activity. The compounds are selected and grouped according to their cytotoxic, anticancer, antibacterial, antifungal, and miscellaneous effects.

show abstract

Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity

Cited by 55 publications

References 102 publications

Drug re‐engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery

Drug re‐engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery

Synthetic and natural coumarins as potent anticonvulsant agents: A review with structure–activity relationship

Coumarins as Fungal Metabolites with Potential Medicinal Properties

Contact Info

Product

Resources

About